ANIP (ANI Pharmaceuticals) Other Stockholders Equity : $0.0 Mil (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Other Stockholders Equity?

ANI Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.0 Mil.

ANI Pharmaceuticals's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.0 Mil) to Sep. 2024 ($0.0 Mil) but then stayed the same from Sep. 2024 ($0.0 Mil) to Dec. 2024 ($0.0 Mil).

ANI Pharmaceuticals's annual Other Stockholders Equity increased from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($0.0 Mil) but then declined from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil).

ANI Pharmaceuticals Other Stockholders Equity Historical Data

The historical data trend for ANI Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Other Stockholders Equity Chart

ANI Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Get a 7-Day Free Trial

ANI Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

ANI Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

ANI Pharmaceuticals Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Executives

Krista Davis	officer: SVP, CHIEF HR OFFICER	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook	officer: SR. VP, GENERAL COUNSEL & SEC.	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg	officer: SVP, GENERICS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Stephen P. Carey	officer: Vice President and CFO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Nikhil Lalwani	director, officer: PRESIDENT & CEO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Christopher Mutz	officer: HEAD OF RARE DISEASE	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Muthusamy Shanmugam	director, officer: HEAD OF R&D, COO-NOVITIUM OPS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert	officer: SVP - CORP. DEV. & STRATEGY	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
James G. Marken	officer: Vice President, Operations	210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Antonio R Pera	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Matthew J Leonard	director	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp	10 percent owner
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780